|  |  |
| --- | --- |
| SHARED CARE AGREEMENT |  |
| Name of medicine | Insert here |
| Indication | Insert here |
| Version: XX Approval date: Month YEAR Review date: Month YEAR |

The Shared Care Agreement (SCA) is intended to facilitate the accessibility and safe prescribing of complex treatments across the secondary/primary care interface. It does not contain all of the relevant product information, which should be sought using the current British National Formulary and manufacturer’s Summary of Product Characteristics. The SCA must be used in conjunction with the NHS Lothian Procedure for the Shared Care of Medicines, available [here](https://policyonline.nhslothian.scot/Policies/Pages/safe-use-of-medicines-policy.aspx#tab3).

|  |
| --- |
| Roles and responsibilities  |
| Listed below are specific responsibilities that are additional to those included in the NHS Lothian Policy and Procedures for Shared Care. Please refer to the policy for core roles and responsibilities that apply to all Shared Care Agreements.Consultant

|  |
| --- |
| *Please give specific information where this will be helpful to the primary care prescribers, e.g.* *Initiation of therapy with ‘drug x’ over a one-month period, then supply of the medicine for one further month once the patient’s treatment is stable* *Patient monitoring – 3 monthly for the first 12 months, then 6 monthly in the longer term*  |

**General Practitioners and primary care non-medical prescribers**Patient, relatives, carers

|  |
| --- |
|  *If there are no specific responsibilities that are additional to those included in the NHS Lothian Policy and Procedures for Shared Care, please include the statement ‘As listed in NHS Lothian Policy and Procedures for the Shared Care of Medicines’*  |

 |

|  |
| --- |
| Support and Advice for the GP and primary care non-medical prescribers |
|

|  |
| --- |
| *e.g. Contact points, telephone numbers, supportive guidance*  |

 |

|  |
| --- |
| Key Information on the Medicine |
| Refer to current edition of the British National Formulary (BNF), available at [www.bnf.org](http://www.bnf.org), and Summary of Product Characteristics (SPC), available at [www.medicines.org.uk](http://www.medicines.org.uk) for detailed product and prescribing information and specific guidance.Background to disease and use of drug for the given indication

|  |
| --- |
|  *Brief paragraph*  |

Indication

|  |
| --- |
|  *Specific to approved use in NHS Lothian (check formulary status)* |

Dosage and administration*Include only where no SPC is available, i.e. for unlicensed /off-label use, and in line with approved use in NHS Lothian* Monitoring

|  |  |  |  |
| --- | --- | --- | --- |
| **Test** | **Frequency**  | **Abnormal result** | **Action if abnormal result** |
|  |  |  |  |
|  |  |  |  |

Cautions, contraindications - Refer to current Summary of Product Characteristics: [www.medicines.org.uk](http://www.medicines.org.uk) Fertility, Pregnancy and LactationRefer to current Summary of Product Characteristics: [www.medicines.org.uk](http://www.medicines.org.uk) for full detail.VaccinationAdverse effects-Refer to current Summary of Product Characteristics: [www.medicines.org.uk](http://www.medicines.org.uk) for full detail.Drug interactions-Refer to current Summary of Product Characteristics: [www.medicines.org.uk](http://www.medicines.org.uk) for full detail. |

The presence of this SCA does not compel a primary care prescriber to prescribe if they feel that it is out with the scope of their competencies (as per GMC guidance on safe prescribing) or resources, as ultimate responsibility lies with the prescribing, not the recommending, clinician.

Approved by the XX Committee on XX.X.XX *(delete if not applicable)*

Approved by the General Practice Prescribing Committee (GPPC) on XX.X.XX